The miR-30d-3p is a known prognostic biomarker for MM reported to have lower serum expression levels and tumor suppressor functions mediated through direct targeting of TP53 and MTDH/PI3K/Akt signaling pathway59. This evidence concerns the gene TP53 and Miyoshi myopathy.